• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Ranbaxy Laboratories > September 16, 2005

      Ranbaxy may tap Shasun for epilepsy drug supply

      Posted AtIndian Business Standard

      Ranbaxy Laboratories, which has received US FDA approval to tap the $964 million gabapentin market, is in talks with the Chennai-based Shasun Chemicals and Drugs to outsource the anti-epilepsy generic blockbuster for the US.

      Ranbaxy has received the US FDA generic drugs wing's approval to manufacture and market gabapentin tablets of 600 and 800 mg strengths. In the US, Ranbaxy will compete with Neurontin, the gabapentin brand of Pfizer Pharmaceuticals Inc, the inventor company.

      Total sales for gabapentin in the US were $2.2 billion and the market size of gabapentin tablets of 600 and 800 mg was estimated at $964 million.

      "Since the US market for gabapentin tablet was huge, the annual business volume involved in the outsourcing deal between Shasun and Ranbaxy would be substantial" said an industry analyst.

      Shasun Chemicals is one of the leading manufacturers of gabapentin bulk in India.

      Currently, the company has long-standing business arrangements with domestic and multinational innovator companies in other active pharmaceuticals ingredient supply and contract manufacturing.

      Industry sources said Shasun was in talks with two Indian companies interested to market gabapentin generic in the US.

      These companies are learnt to have filed the DMFs for the product with the USFDA for approval. Ranbaxy sources declined to comment on the product sourcing arrangement for gabapentin.

      However, commenting on the USFDA approval for gabapentin, Jim Meehan, vice-president of sales and marketing for Ranbaxy Pharmaceutical Inc, USA, said in a release that the company would focus on maximising the value of this formulation to the company that will have a positive impact on the company performance for the balance of this year.

      "Ranbaxy will begin shipping this affordable generic alternative immediately," he informed.

      About the product sourcing arrangement for Ranbaxy, Shasun sources said "We have not yet signed the product supply deal and, thus, do not want to comment on the same at this point of time."

      September 16, 2005


      Share this Article!

    Back to top^